Epoetin Theta in Anaemic Cancer Patients Receiving Platinum-Based Chemotherapy: A Randomised Controlled Trial
2010

Epoetin Theta for Anemia in Cancer Patients

Sample size: 223 publication 10 minutes Evidence: moderate

Author Information

Author(s): Tjulandin Sergei A MD, Bias Peter MD, Elsässer Reiner Dipl.Stat., Gertz Beate PhD, Kohler Erich PhD, Buchner Anton PhD

Primary Institution: Russian Cancer Research Center

Hypothesis

Epoetin theta is superior to placebo in treating anemia in cancer patients receiving platinum-based chemotherapy.

Conclusion

Epoetin theta is a safe and effective treatment for symptomatic anemia due to platinum-based chemotherapy in cancer patients.

Supporting Evidence

  • Epoetin theta showed a complete hemoglobin response in 65.8% of patients compared to 20.3% in the placebo group.
  • Epoetin beta was also effective, with a 71.2% response rate compared to placebo.
  • The mean dose of Epoetin theta at complete response was lower than that of Epoetin beta.

Takeaway

This study tested a new medicine called Epoetin theta to help cancer patients with anemia, and it worked better than a fake treatment.

Methodology

223 patients were randomly assigned to receive Epoetin theta, Epoetin beta, or placebo for 12 weeks, with the primary endpoint being the complete hemoglobin response.

Potential Biases

Potential bias due to the unblinding of the person administering the treatment.

Limitations

The study had a relatively small sample size and was limited to specific cancer types.

Participant Demographics

Patients were adults aged 18 and older with solid tumors and secondary anemia due to chemotherapy.

Statistical Information

P-Value

<0.0001

Confidence Interval

8.06 (3.89, 17.63)

Statistical Significance

p<0.0001

Digital Object Identifier (DOI)

10.1111/j.1753-5174.2010.00030.x

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication